IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
KRAS G12C Mutations
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the KRAS G12C Mutations cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab M.D. Anderson Cancer Center | Phase 1/2 | CC |
Adagrasib M.D. Anderson Cancer Center | Phase 1/2 | CC |
kqb368 Kumquat Biosciences Inc. | Phase 1 | CC |
Same molecule, other indications
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →